Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
AstraZeneca
Merck
Dow
Chinese Patent Office
Harvard Business School
Fish and Richardson
Covington
Federal Trade Commission
Accenture

Generated: January 17, 2018

DrugPatentWatch Database Preview

Baxter Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for BAXTER HLTHCARE, and what generic alternatives to BAXTER HLTHCARE drugs are available?

BAXTER HLTHCARE has one hundred and ninety-two approved drugs.

There are six US patents protecting BAXTER HLTHCARE drugs. There are two tentative approvals on BAXTER HLTHCARE drugs.

There are one hundred and fifteen patent family members on BAXTER HLTHCARE drugs in thirty-five countries and one hundred and forty-eight supplementary protection certificates in twelve countries.

Summary for Baxter Hlthcare
International Patents:115
US Patents:6
Tradenames:302
Ingredients:109
NDAs:192

Drugs and US Patents for Baxter Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER gentamicin sulfate INJECTABLE;INJECTION 062373-005 Sep 7, 1982 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Baxter Hlthcare CYTOXAN cyclophosphamide INJECTABLE;INJECTION 012142-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Baxter Hlthcare ETHRANE enflurane LIQUID;INHALATION 017087-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Baxter Hlthcare CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER amino acids; dextrose INJECTABLE;INJECTION 020734-001 Sep 29, 1997 RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Baxter Hlthcare POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate INJECTABLE;INJECTION 019367-005 Apr 5, 1985 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Baxter Hlthcare MEPERIDINE HYDROCHLORIDE meperidine hydrochloride INJECTABLE;INJECTION 088282-001 Jun 15, 1984 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Baxter Hlthcare CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER amino acids; dextrose INJECTABLE;INJECTION 020734-007 Sep 29, 1997 RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Baxter Hlthcare DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER dextrose; potassium chloride; sodium chloride INJECTABLE;INJECTION 018629-007 Mar 23, 1982 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Baxter Hlthcare SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER potassium chloride; sodium chloride INJECTABLE;INJECTION 017648-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Baxter Hlthcare Corp FLUCONAZOLE IN SODIUM CHLORIDE 0.9% fluconazole INJECTABLE;INJECTION 077947-002 May 26, 2010 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Baxter Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare ETHRANE enflurane LIQUID;INHALATION 017087-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-003 Aug 15, 1988 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-002 Dec 30, 1988 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare BRANCHAMIN 4% amino acids INJECTABLE;INJECTION 018678-001 Sep 28, 1984 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX/MESNEX KIT ifosfamide; mesna INJECTABLE;INJECTION 019763-003 Oct 10, 1992 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-002 Dec 30, 1988 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare Corp PRALIDOXIME CHLORIDE pralidoxime chloride INJECTABLE;INJECTION 018799-001 Dec 13, 1982 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare CYTOXAN (LYOPHILIZED) cyclophosphamide INJECTABLE;INJECTION 012142-009 Dec 10, 1985 ➤ Subscribe ➤ Subscribe
Baxter Hlthcare MESNEX mesna TABLET;ORAL 020855-001 Mar 21, 2002 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags ➤ Subscribe 1/31/2014
➤ Subscribe Inhalation 99.90% ➤ Subscribe 9/11/2008

Non-Orange Book US Patents for Baxter Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,886,789 Peritoneal dialysis and compositions for use therein ➤ Subscribe
8,410,077 Sulfoalkyl ether cyclodextrin compositions ➤ Subscribe
9,750,822 Sulfoalkyl ether cyclodextrin compositions ➤ Subscribe
9,200,088 Sulfoalkyl ether cyclodextrin compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Baxter Hlthcare Drugs

Supplementary Protection Certificates for Baxter Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/002 United Kingdom ➤ Subscribe PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
2014 00050 Denmark ➤ Subscribe PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
C/GB05/044 United Kingdom ➤ Subscribe PRODUCT NAME: HEXYL AMINOLEVULINATE, OPTIONALLY IN THE FORM OF A SALT, PREFERABLY HEXYL AMINOLEVULINATE HYDROCHLORIDE; REGISTERED: SE 19227 20040917; UK PL 18952/0003 20050714
0612 Netherlands ➤ Subscribe PRODUCT NAME: 4-AMINOPYRIDINE, DAN WEL EEN DERIVAAT DAARVAN, IN HET BIJZONDER EEN ZOUT, SOLVAAT OF PRODRUG; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720
C/GB06/032 United Kingdom ➤ Subscribe PRODUCT NAME: ENTECAVIR-(2-AMINO-1,9-DIHYDRO-9-((1S,3R,4S)-4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENE CYCLOPENTYL)-6H-PURIN-6-ONE AND HYDRATES THEREOF, PARTICULARLY THE MONOHYDRATE; REGISTERED: UK EU/1/06/343/001 20060626; UK EU/1/06/343/002 20060626; UK EU/1/06/343/003 20060626; UK EU/1/06/343/004 20060626; UK EU/1/06/343/005 20060626
C/GB97/078 United Kingdom ➤ Subscribe PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
0822 Netherlands ➤ Subscribe PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
2008006 Lithuania ➤ Subscribe PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
C0055 France ➤ Subscribe PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
C/GB11/004 United Kingdom ➤ Subscribe PRODUCT NAME: MANNITOL; REGISTERED: SE 22708 20061020; UK PL 27944/0001-0001 20071218
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Cipla
Chinese Patent Office
Federal Trade Commission
Citi
Fish and Richardson
Novartis
Merck
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot